{"preliminary_commentary":{"by_channel":{"x_thread":130,"podcast":5,"youtube":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01584258\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T03:01:37.733Z","note":"Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.","passages_read":null,"text":"The commentary discusses PACE-A’s comparison of SBRT with prostatectomy and how to place it alongside other prostate radiotherapy trials. Topics include cancer-control measures, patient-reported urinary, sexual and bowel outcomes, treatment choice, and shared decision-making. A speaker questions whether continence was an appropriate co-primary endpoint given the different effects of surgery and radiotherapy. Discussion also addresses the change in primary endpoint, the trial’s shortfall from its planned enrollment, and whether the available evidence can establish equivalence."},"name":"PACE","nct_id":"NCT01584258","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pace-nct01584258. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PACE","arms":[{"description":"Low and intermediate risk patients, for whom surgery is considered, will be randomised to prostatectomy vs prostate SBRT delivered with 36.25 Gy in 5 fractions.","label":"PACE-A: Prostatectomy vs prostate SBRT","type":"ACTIVE_COMPARATOR"},{"description":"Low and intermediate risk patients, for whom surgery is not considered or who refuse surgery, will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 78 Gy in 39 fractions or 62 Gy in 20 fractions vs SBRT delivered with 36.25 Gy in 5 fractions.","label":"PACE-B: Conventionally Fractionated RT vs Prostate SBRT","type":"ACTIVE_COMPARATOR"},{"description":"Intermediate and high risk patients, indicated for 6 months ADT, will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 60 Gy in 20 fractions vs SBRT delivered with 36.25 Gy in 5 fractions.","label":"PACE-C: Conventionally Fractionated RT vs Prostate SBRT","type":"ACTIVE_COMPARATOR"}],"collaborators":["The Institute of Cancer Research, Sutton, Surrey, UK"],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":2205,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Prostatectomy","otherNames":[],"type":"PROCEDURE"},{"name":"Conventionally Fractionated Prostate Radiotherapy","otherNames":[],"type":"RADIATION"},{"name":"Prostate SBRT","otherNames":[],"type":"RADIATION"}],"last_update":"2024-01-19","lead_sponsor":"Royal Marsden NHS Foundation Trust","official_title":"International Randomised Study of Prostatectomy vs Stereotactic Body Radiotherapy (SBRT) and Conventionally Fractionated Radiotherapy vs SBRT for Organ-Confined Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PACE-B and PACE-C: Freedom from biochemical or clinical failure","timeFrame":"5 years from randomisation (primary timepoint)"},{"measure":"PACE-A: Co-primary patient reported outcomes of urinary incontinence and bowel bother","timeFrame":"2 years from treatment (primary timepoint)"}],"references":[{"citation":"Tree AC, Hinder V, Chan A, Tolan S, Ostler P, van der Voet H, Kancherla K, Loblaw A, Naismith O, Jain S, Martin A, Price D, Brand D, Chu W, Duffton A, Kelly P, O'Neill B, Staffurth J, Sasso G, Pugh J, Manning G, Brown S, Burnett S, Griffin C, Hall E, van As N; PACE Investigators. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2025 Jul;26(7):936-947. doi: 10.1016/S1470-2045(25)00205-0. Epub 2025 Jun 12.","pmid":"40517778","type":"DERIVED"},{"citation":"Smith RP, Mohammed MA, Beriwal S, Benoit RM. Prostate Brachytherapy With Cs-131: Long-term Results Compared With Published Stereotactic Body Radiotherapy Data. Am J Clin Oncol. 2025 Jan 1;48(1):34-37. doi: 10.1097/COC.0000000000001145. Epub 2024 Oct 17.","pmid":"39716881","type":"DERIVED"},{"citation":"van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Camilleri P, Kancherla K, Frew J, Chan A, Naismith O, Armstrong J, Staffurth J, Martin A, Dayes I, Wells P, Price D, Williamson E, Pugh J, Manning G, Brown S, Burnett S, Hall E. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N Engl J Med. 2024 Oct 17;391(15):1413-1425. doi: 10.1056/NEJMoa2403365.","pmid":"39413377","type":"DERIVED"},{"citation":"Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13.","pmid":"36113498","type":"DERIVED"},{"citation":"Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17.","pmid":"31540791","type":"DERIVED"}],"start_date":{"date":"2012-08-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Prostate Advances in Comparative Evidence","url":"https://clinicaltrials.gov/study/NCT01584258"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pace-nct01584258"}